Skip to main content
Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval? JAMA Schulman, K. A., Greicius, M. D., Richman, B. 2021

View details for DOI 10.1001/jama.2021.11768

View details for PubMedID 34279572